NEW YORK–(BUSINESS WIRE)– IRX Therapeutics, Inc. (IRX) today announced that Mark Leuchtenberger,
the Company’s President and Chief Executive Officer, will present a
corporate overview at the BioCentury 24th Annual Future
Leaders in the Biotech Industry Conference on Friday, April 7, 2017, at
3:00 p.m. Eastern time. The conference will be held at the Millennium
Broadway Hotel & Conference Center in New York City.
About IRX Therapeutics
IRX Therapeutics is a clinical-stage company developing novel
immunotherapies focused on reducing the immune suppression that is seen
in the cancer tumor micro-environment, restoring immune function, and
activating a coordinated immune response against the tumor. The lead
candidate, IRX-2, is a proprietary therapeutic containing numerous
active cytokine components. Data collected to date indicates that IRX-2
acts to restore and activate multiple immune cell types, including T
cells, dendritic cells, and natural killer cells, to recognize and
destroy tumors. For more information about the Company and its clinical
programs, please visit www.IRXTherapeutics.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170403005935/en/
Source: IRX Therapeutics, Inc.
Cet article IRX Therapeutics to Present at the BioCentury 24th
Annual Future Leaders in the Biotech Industry Conference est apparu en premier sur EEI-BIOTECHFINANCES.